S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.39 (+1.95%)
AAPL   172.10 (+2.14%)
MSFT   291.91 (+1.70%)
META   180.50 (+1.70%)
GOOGL   121.68 (+2.39%)
AMZN   143.55 (+2.07%)
TSLA   900.09 (+4.68%)
NVDA   187.09 (+4.27%)
NIO   21.11 (+1.39%)
BABA   94.77 (-0.11%)
AMD   100.83 (+2.76%)
MU   65.04 (+4.36%)
T   18.27 (+1.27%)
CGC   3.30 (+4.76%)
GE   79.93 (+1.31%)
F   16.18 (+2.21%)
DIS   121.57 (+3.30%)
AMC   24.44 (-3.97%)
PYPL   101.10 (+2.01%)
PFE   50.11 (+3.77%)
NFLX   249.30 (+2.72%)
S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.39 (+1.95%)
AAPL   172.10 (+2.14%)
MSFT   291.91 (+1.70%)
META   180.50 (+1.70%)
GOOGL   121.68 (+2.39%)
AMZN   143.55 (+2.07%)
TSLA   900.09 (+4.68%)
NVDA   187.09 (+4.27%)
NIO   21.11 (+1.39%)
BABA   94.77 (-0.11%)
AMD   100.83 (+2.76%)
MU   65.04 (+4.36%)
T   18.27 (+1.27%)
CGC   3.30 (+4.76%)
GE   79.93 (+1.31%)
F   16.18 (+2.21%)
DIS   121.57 (+3.30%)
AMC   24.44 (-3.97%)
PYPL   101.10 (+2.01%)
PFE   50.11 (+3.77%)
NFLX   249.30 (+2.72%)
S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.39 (+1.95%)
AAPL   172.10 (+2.14%)
MSFT   291.91 (+1.70%)
META   180.50 (+1.70%)
GOOGL   121.68 (+2.39%)
AMZN   143.55 (+2.07%)
TSLA   900.09 (+4.68%)
NVDA   187.09 (+4.27%)
NIO   21.11 (+1.39%)
BABA   94.77 (-0.11%)
AMD   100.83 (+2.76%)
MU   65.04 (+4.36%)
T   18.27 (+1.27%)
CGC   3.30 (+4.76%)
GE   79.93 (+1.31%)
F   16.18 (+2.21%)
DIS   121.57 (+3.30%)
AMC   24.44 (-3.97%)
PYPL   101.10 (+2.01%)
PFE   50.11 (+3.77%)
NFLX   249.30 (+2.72%)
S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.39 (+1.95%)
AAPL   172.10 (+2.14%)
MSFT   291.91 (+1.70%)
META   180.50 (+1.70%)
GOOGL   121.68 (+2.39%)
AMZN   143.55 (+2.07%)
TSLA   900.09 (+4.68%)
NVDA   187.09 (+4.27%)
NIO   21.11 (+1.39%)
BABA   94.77 (-0.11%)
AMD   100.83 (+2.76%)
MU   65.04 (+4.36%)
T   18.27 (+1.27%)
CGC   3.30 (+4.76%)
GE   79.93 (+1.31%)
F   16.18 (+2.21%)
DIS   121.57 (+3.30%)
AMC   24.44 (-3.97%)
PYPL   101.10 (+2.01%)
PFE   50.11 (+3.77%)
NFLX   249.30 (+2.72%)
NYSE:RMD

ResMed - RMD Stock Forecast, Price & News

$239.99
-0.86 (-0.36%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$231.19
$240.69
50-Day Range
$196.23
$243.58
52-Week Range
$189.40
$301.34
Volume
755,604 shs
Average Volume
590,474 shs
Market Capitalization
$35.11 billion
P/E Ratio
45.20
Dividend Yield
0.70%
Price Target
$266.40

ResMed MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.56 Rating Score
Upside/​Downside
11.0% Upside
$266.40 Price Target
Short Interest
Healthy
1.27% of Float Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
-0.86
Upright™ Environmental Score
News Sentiment
0.29mentions of ResMed in the last 14 days
Based on 25 Articles This Week
Insider Trading
Selling Shares
$6.93 M Sold Last Quarter
Proj. Earnings Growth
14.96%
From $5.75 to $6.61 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.51 out of 5 stars

Medical Sector

186th out of 1,117 stocks

Surgical & Medical Instruments Industry

14th out of 113 stocks

RMD stock logo

About ResMed (NYSE:RMD) Stock

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME)to streamline their sleep programs; and connectivity module and propeller solutions. In addition, it offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice agencies, as well as related accountable care organizations; and HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies. The company markets its products primarily to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

ResMed Price Performance

Shares of ResMed stock opened at $240.85 on Friday. ResMed has a twelve month low of $189.40 and a twelve month high of $301.34. The stock has a market capitalization of $35.23 billion, a P/E ratio of 45.36, a PEG ratio of 2.28 and a beta of 0.47. The company has a current ratio of 2.55, a quick ratio of 1.56 and a debt-to-equity ratio of 0.20. The business's fifty day moving average price is $219.87 and its 200 day moving average price is $226.14.

ResMed (NYSE:RMD - Get Rating) last issued its earnings results on Thursday, August 11th. The medical equipment provider reported $1.49 earnings per share for the quarter, beating analysts' consensus estimates of $1.48 by $0.01. ResMed had a return on equity of 26.91% and a net margin of 22.02%. The firm had revenue of $914.74 million for the quarter, compared to analysts' expectations of $912.53 million. During the same quarter last year, the firm earned $1.35 earnings per share. The firm's revenue for the quarter was up 4.4% compared to the same quarter last year. As a group, research analysts anticipate that ResMed will post 5.75 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on RMD shares. Royal Bank of Canada raised ResMed from a "sector perform" rating to an "outperform" rating and increased their target price for the stock from $233.00 to $244.00 in a research note on Monday, June 6th. StockNews.com downgraded ResMed from a "buy" rating to a "hold" rating in a research note on Tuesday. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $264.80.

Insider Buying and Selling at ResMed

In other ResMed news, insider David Pendarvis sold 1,545 shares of the firm's stock in a transaction dated Friday, June 3rd. The stock was sold at an average price of $209.44, for a total value of $323,584.80. Following the transaction, the insider now directly owns 108,376 shares of the company's stock, valued at $22,698,269.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, insider David Pendarvis sold 1,545 shares of ResMed stock in a transaction dated Friday, June 3rd. The stock was sold at an average price of $209.44, for a total value of $323,584.80. Following the completion of the transaction, the insider now directly owns 108,376 shares in the company, valued at $22,698,269.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Michael J. Farrell sold 5,675 shares of ResMed stock in a transaction that occurred on Monday, May 16th. The shares were sold at an average price of $196.61, for a total value of $1,115,761.75. Following the completion of the transaction, the chief executive officer now owns 405,260 shares of the company's stock, valued at $79,678,168.60. The disclosure for this sale can be found here. Insiders have sold 29,160 shares of company stock valued at $6,327,758 over the last three months. 1.42% of the stock is owned by company insiders.

Receive RMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ResMed and its competitors with MarketBeat's FREE daily newsletter.

RMD Stock News Headlines

ResMed: Fiscal Q4 Earnings Snapshot - Greenwich Time
ResMed (NYSE:RMD) Stock Rating Lowered by StockNews.com
ResMed (RMD) Scheduled to Post Quarterly Earnings on Thursday
StockNews.com Upgrades ResMed (NYSE:RMD) to Buy
Brokerages Set ResMed Inc. (NYSE:RMD) Target Price at $260.67
See More Headlines
Receive RMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ResMed and its competitors with MarketBeat's FREE daily newsletter.

RMD Company Calendar

Ex-Dividend for 6/16 Dividend
5/11/2022
Dividend Payable
6/16/2022
Last Earnings
8/11/2022
Today
8/12/2022
Ex-Dividend for 9/22 Dividend
8/17/2022
Dividend Payable
9/22/2022
Next Earnings (Estimated)
10/27/2022
Fiscal Year End
6/30/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Sector
Medical
CUSIP
76115210
Employees
7,970
Year Founded
1989

Price Target and Rating

Average Stock Price Forecast
$266.40
High Stock Price Forecast
$280.00
Low Stock Price Forecast
$250.00
Forecasted Upside/Downside
+11.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.56
Research Coverage
9 Analysts

Profitability

Net Income
$474.51 million
Pretax Margin
27.17%

Debt

Sales & Book Value

Annual Sales
$3.20 billion
Cash Flow
$6.58 per share
Book Value
$19.83 per share

Miscellaneous

Free Float
144,208,000
Market Cap
$35.11 billion
Optionable
Optionable
Beta
0.47

Social Links


Key Executives














RMD Stock - Frequently Asked Questions

Should I buy or sell ResMed stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ResMed in the last twelve months. There are currently 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" RMD shares.
View RMD analyst ratings
or view top-rated stocks.

What is ResMed's stock price forecast for 2022?

9 brokers have issued twelve-month target prices for ResMed's stock. Their RMD share price forecasts range from $250.00 to $280.00. On average, they anticipate the company's share price to reach $266.40 in the next year. This suggests a possible upside of 12.5% from the stock's current price.
View analysts price targets for RMD
or view top-rated stocks among Wall Street analysts.

How have RMD shares performed in 2022?

ResMed's stock was trading at $260.48 at the beginning of the year. Since then, RMD stock has decreased by 9.1% and is now trading at $236.84.
View the best growth stocks for 2022 here
.

Are investors shorting ResMed?

ResMed saw a increase in short interest during the month of July. As of July 31st, there was short interest totaling 1,840,000 shares, an increase of 18.7% from the July 15th total of 1,550,000 shares. Based on an average daily volume of 577,500 shares, the short-interest ratio is presently 3.2 days. Approximately 1.3% of the shares of the company are short sold.
View ResMed's Short Interest
.

When is ResMed's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 27th 2022.
View our RMD earnings forecast
.

How were ResMed's earnings last quarter?

ResMed Inc. (NYSE:RMD) issued its quarterly earnings data on Thursday, August, 11th. The medical equipment provider reported $1.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.48 by $0.01. The medical equipment provider had revenue of $914.74 million for the quarter, compared to analysts' expectations of $912.53 million. ResMed had a trailing twelve-month return on equity of 26.91% and a net margin of 22.02%. The firm's revenue was up 4.4% on a year-over-year basis. During the same quarter last year, the firm earned $1.35 EPS.

How often does ResMed pay dividends? What is the dividend yield for ResMed?

ResMed declared a quarterly dividend on Thursday, April 28th. Shareholders of record on Thursday, May 12th will be paid a dividend of $0.42 per share on Thursday, June 16th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 0.71%. The ex-dividend date of this dividend is Wednesday, May 11th.
Read our dividend analysis for RMD
.

Is ResMed a good dividend stock?

ResMed (NYSE:RMD) pays an annual dividend of $1.68 per share and currently has a dividend yield of 0.69%. The company does not yet have a strong track record of dividend growth. The dividend payout ratio is 31.64%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, RMD will have a dividend payout ratio of 25.42% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for RMD.

What is Mick Farrell's approval rating as ResMed's CEO?

284 employees have rated ResMed Chief Executive Officer Mick Farrell on Glassdoor.com. Mick Farrell has an approval rating of 92% among the company's employees. This puts Mick Farrell in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of ResMed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ResMed investors own include NVIDIA (NVDA), Walt Disney (DIS), Intel (INTC), AbbVie (ABBV), Netflix (NFLX), Adobe (ADBE), Visa (V), Alibaba Group (BABA), PayPal (PYPL) and QUALCOMM (QCOM).

What is ResMed's stock symbol?

ResMed trades on the New York Stock Exchange (NYSE) under the ticker symbol "RMD."

Who are ResMed's major shareholders?

ResMed's stock is owned by a number of institutional and retail investors. Top institutional shareholders include FMR LLC (5.14%), JPMorgan Chase & Co. (0.76%), Swiss National Bank (0.43%), Sumitomo Mitsui Trust Holdings Inc. (0.41%), Congress Asset Management Co. MA (0.39%) and Deutsche Bank AG (0.27%). Insiders that own company stock include Brett Sandercock, Carol Burt, Dave Michaud, David Pendarvis, James Hollingshead, Justin Leong, Michael J Farrell, Michael J Farrell, Rajwant Sodhi, Richard Mchale, Robert Andrew Douglas and Ronald R Taylor.
View institutional ownership trends
.

How do I buy shares of ResMed?

Shares of RMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ResMed's stock price today?

One share of RMD stock can currently be purchased for approximately $236.84.

How much money does ResMed make?

ResMed (NYSE:RMD) has a market capitalization of $34.65 billion and generates $3.20 billion in revenue each year. The medical equipment provider earns $474.51 million in net income (profit) each year or $5.31 on an earnings per share basis.

How many employees does ResMed have?

The company employs 7,970 workers across the globe.

When was ResMed founded?

ResMed was founded in 1989.

How can I contact ResMed?

ResMed's mailing address is 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA, 92123. The official website for the company is www.resmed.com. The medical equipment provider can be reached via phone at (858) 836-5000, via email at investorrelations@resmed.com, or via fax at 858-836-5501.

This page (NYSE:RMD) was last updated on 8/12/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.